New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

Semaglutide also delays gastric emptying ... but the label indicates thyroid cancer risk. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or multiple ...

Ozempic (semaglutide) and Mounjaro (tirzepatide ... doctor to see if these warnings apply to you. Boxed warning: Risk of thyroid cancer Ozempic and Mounjaro both have a boxed warning for the ...

Ozempic (semaglutide) is a brand-name drug ... Ozempic has a boxed warning for risk of thyroid cancer, and metformin has a boxed warning for risk of lactic acidosis. A boxed warning is a serious ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk ... semaglutide injection 2.4 mg contains a Boxed Warning for possible thyroid tumors, including cancer ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

Dr. Michael Greger is famous for several books including “How Not to Die,” and for his website nutritionfacts.org. He ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...